Amyloid imaging in subjects with and at risk for Alzheimer’s disease:- a positron emission tomography (PET) study
Diseases and Conditions Researched
What is the purpose of this trial?
This study is based on the hypothesis that [11C]PIB (Pittsburgh Compound B) is a suitable tracer for imaging amyloid plaques in the brain. The main specific aims of this study are:
1. a) To compare in vivo amyloid-ß burden as measured using [11C]PIB and PET in subjects with mild AD, subjects with MCI, and healthy controls.
b) To study the association between the neuropsychological test performance and [11C]PIB uptake in subjects with mild AD and MCI.
2. a) To study in vivo amyloid-ß burden as measured using [11C]PIB and PET in healthy subjects with a family history of AD in a first degree relative and who are homozygous or heterozygous for the APOE ε4 and in subjects who lack this allele.
b) To examine neuropsychological test performance in healthy subjects with family history of AD, as a function of APOE ε4 status
This trial accepts healthy volunteers.
Click here for detailed participation information for this trial.
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.